Giredestrant plus Everolimus in Advanced Breast Cancer
NEJM,
10.0 months with giredestrant + everolimus
Median progression-free survival, ESR1-mutated
versus 5.5 months with standard endocrine therapy + everolimus
Take-home
A phase 3 trial evaluated giredestrant plus everolimus versus standard endocrine therapy plus everolimus in patients with ER-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor.
Giredestrant significantly improved progression-free survival, particularly in patients with ESR1-mutated tumors: 10.0 versus 5.5 months.
Benefits were also observed across the overall population, while adverse-event rates were broadly similar between treatment groups.







